Pacira (PCRX) BioSciences announced an exclusive worldwide license and collaboration agreement with AmacaThera for the development and commercialization of AMT-143, a novel long-acting formulation of the non-opioid analgesic ropivacaine for postsurgical pain control. Under the terms of the agreement, Pacira will fund clinical development through to commercial launch and the companies will collaborate on Phase 2 clinical development. AmacaThera will receive an upfront payment of $5 million with the potential for future development- and sales-based milestone payments and a tiered royalty on future net sales.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PCRX:
- Pacira presents updated three-year results of PCRX-201
- Pacira (PCRX) Q3 Earnings Cheat Sheet
- Pacira’s Pediatric Analgesia Study: A Potential Game-Changer for Postoperative Pain Management
- Pacira’s Innovative Study on Knee OA Pain Management: What Investors Need to Know
- Pacira’s Phase 2 Study: A New Approach to Hip Osteoarthritis Treatment